Aktuellt
SENASTE
Redeye’s first take on the Q4 report this morning. Cellavision presented a markedly stronger report straight through the accounts. The top line, finally driven by good development in all regions, was strong, with a healthy 29% organic growth. The gross margin was 68%, which aligned with our expectations. The costs were mostly in line with higher R&D expenses, although there was no enormous difference. Cellavision’s cash flow was positively impacted again by decreased tied-up capital in inventory. The operating cash flow in the quarter amounted to SEK76m (28m). We expect to have a slightly more positive stance on sales progression in 2024e, increasing our base case by roughly 5-10%.
LÄS MER
